Skip to content
Screener

NovoCure NVCR Q1 2026 earnings

Reported April 30, 2026 · Before market open

Revenue$174.1MBeat by $6.3M
EPS-$0.62Miss by $0.11
Revenue estimate$167.8M
EPS estimate-$0.51

Next report

Oct 29, 2026 (in a month)
Revenue estimate$182.3M
EPS estimate-$0.21

Financials

Q1 2026

Income statement

See full
Revenue$174.1M+12.3%
Gross profit$135.1M+16.0%
Operating income-$67.4M-78.1%
Net income-$71.1M-107%
EPS (diluted)-$0.62-100%

Balance sheet

See full
Cash & equivalents$87.5M-31.2%
Total debt$39.5M-2.1%
Total equity$330.7M-8.6%
Total assets$787.9M-36.9%

Cash flow

See full
Operating cash flow-$13.5M+62.1%
CapEx$5.2M-51.4%
Free cash flow-$18.7M+59.7%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$1.24B-36.7%
Enterprise value$1.19B-36.3%
P/S1.8×-1.3×

Profitability

See full
Gross margin75.2%-2.0pp
Operating margin-27.2%+0.4pp
Net margin-25.7%-0.7pp
FCF margin-7.1%-2.0pp

Returns & leverage

See full
Return on equity-50%+5.4pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

FAQ

When did NovoCure report Q1 2026 earnings?
NovoCure (NVCR) reported Q1 2026 earnings on April 30, 2026 before market open.
What were NovoCure's Q1 2026 revenue and EPS?
NovoCure reported revenue of $174.1M and eps of $-0.62 for Q1 2026.
Did NovoCure beat estimates in Q1 2026?
Revenue beat the consensus estimate of $167.8M by $6.3M. EPS missed the consensus estimate of $-0.51 by $0.11.
How did NovoCure's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 12.3% from $155.0M a year earlier and eps declined 100.0% from $-0.31.
Where can I find NovoCure's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001645113-26-000043) and the 10-Q periodic report (0001645113-26-000042) directly on SEC EDGAR. The filing index links above go to sec.gov.